利图西马布参考与生物类似剂用于瘤学和非瘤学指示的使用
Bonnie A Labdi1, Rim A Elbeshbeshy, Michelle Winkler
1MJH Life Sciences, 2 Clarke Dr, Ste 100, Cranbury, NJ 08512.
The American journal of managed care
|November 10, 2023
概括
瑞图西马布生物类似药的使用正在增加,特别是在瘤学和非学术环境中. 这项研究是首次分析了与参考产品相比,美国三种rituximab生物类似药的现实世界利用情况.
科学领域:
- 药物经济学和健康经济学
- 瘤学和血液学 在线
- 免疫学和风湿病学
背景情况:
- 与参考产品相比,在不同适应症中对rituximab生物类似剂的采用存在有限的现实数据.
- 现有的研究主要集中在瘤学上,在了解非瘤学使用模式方面存在差距.
- 这项研究提供了对使用美国批准的三种rituximab生物类似药与参考rituximab的首次全面分析.
研究的目的:
- 为了比较rituximab生物类似药 (rituximab-abbs,rituximab-pvvr,rituximab-arrx) 与参考产品的实际使用情况.
- 通过指示 (瘤学与非瘤学),标签 (在标签上与非标签上) 和医疗保健环境 (学术与非学术) 来分析采用趋势和模式.
主要方法:
- 2018年12月至2022年2月期间使用非识别的实体数据对rituximab及其生物类似药物的比较分析.
- 数据来自Trisus药物比较,涵盖了193个设施的28,025次接触.
- 主要结局:Rituximab参考与生物类似药的利用,按指示,标签和治疗环境分层.
主要成果:
- 利图西马布基准产品在瘤学 (78.4%) 和非瘤学 (88.3%) 适应症中显示出更高的初始处方率.
- 生物类似药的利用率从2019年的0.01%显著增加到2021年的59.9%,而参考产品的使用量则下降.
- 与学术环境 (10.3%) 相比,在标签上指示 (67.7%) 和非学术环境 (22.2%) 中观察到更高的生物类似药的采用率.
结论:
- 现实世界的证据表明,随着时间的推移,rituximab生物类似药的采用越来越多.
- 生物类似药的吸收在瘤学和非学术医疗环境中更为明显.
- 这些发现突显了不断变化的治疗环境和生物类似药在临床实践中的日益整合.
更多相关视频
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
636
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147
Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
